Evidence map›Paper›PMID 32832735›Full record

ArticleTurkish journal of emergency medicine

Prolongation of QT interval due to hydroxychloroquine overdose used in COVID-19 treatment.

Gökhan Aksel, Mehmet Muzaffer Islam, Tuncay Aslan, Serkan Emre Eroglu

Abstract readCase Reports
In one paragraph

Article in Turkish journal of emergency medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gökhan AkselDepartment of Emergency Medicine, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.ORCID 0000-0002-5580-3201
Mehmet Muzaffer IslamDepartment of Emergency Medicine, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.ORCID 0000-0001-6928-2307
Tuncay AslanDepartment of Emergency Medicine, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.ORCID 0000-0003-0418-8373
Serkan Emre ErogluDepartment of Emergency Medicine, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.ORCID 0000-0002-3183-3713

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydroxychloroquine is one of the most commonly used drugs in COVID-19 treatment. In this case report, we aimed to present a young patient whose QT interval was prolonged due to hydroxychloroquine overdose which was given for COVID-19 treatment. This is the first reported case of QT interval prolongation at a low dose of 1.600 mg in the literature. A 28-year-old male patient was admitted to the emergency department with the complaints of nausea, diarrhea, and weakness. The patient was diagnosed with COVID-19 a day prior and home isolation was recommended with hydroxychloroquine and oseltamivir P. O. treatment. His complaints started 6 h after accidentally taking 1.600 mg of hydroxychloroquine P. O. at the same time. On physical examination, the Glasgow Coma Scale was 15, and neurological, respiratory, and abdominal examinations were normal. His pulse was 54 beats/min, oxygen saturation was 99%, arterial blood pressure was 122/82 mmHg, and fever was 36.5°C. Electrocardiography (ECG) showed sinus bradycardia and corrected QT interval was calculated as 510 ms. The QT interval prolongation and bradycardia persisted, and the patient was hospitalized for follow-up and treatment. He was discharged on the 3

Indexed as

2019 novel coronavirus infectioncoronavirusesCOVID-19COVID-19 pandemicCOVID-19 virus diseaseCOVID-19 virus infectionSARS-CoV-2 infection

Identifiers

PMID32832735
PMCPMC7416852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.